2008
DOI: 10.14219/jada.archive.2008.0312
|View full text |Cite
|
Sign up to set email alerts
|

Reversal of Soft-Tissue Local Anesthesia With Phentolamine Mesylate in Pediatric Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
39
1

Year Published

2011
2011
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 53 publications
(42 citation statements)
references
References 4 publications
2
39
1
Order By: Relevance
“…Phentolamine is a nonselective, alpha-adrenergic blocking agent that has been available in the United States since 1952 for the clinical reversal of accidental extravasation of catecholamines during intravenous administration and for the diagnosis of pheochromocytoma (2,3). The primary action of phentolamine is vasodilation (2)(3)(4).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Phentolamine is a nonselective, alpha-adrenergic blocking agent that has been available in the United States since 1952 for the clinical reversal of accidental extravasation of catecholamines during intravenous administration and for the diagnosis of pheochromocytoma (2,3). The primary action of phentolamine is vasodilation (2)(3)(4).…”
mentioning
confidence: 99%
“…A number of well-controlled studies have shown that phentolamine statistically reduces the time of soft-tissue numbness when compared with a sham treatment (2)(3)(4)(5). Side effects have been reported as minimal and similar to a sham treatment (2)(3)(4)(5).…”
mentioning
confidence: 99%
“…Similar results in additional pediatric subjects (ages 6 to 11 years of age) have been recently reported. 35 In all OraVerse clinical trials, there were no serious adverse events reported. The most common adverse reaction was transient injection site pain.…”
Section: Reversal Of Dental Anesthesiamentioning
confidence: 92%
“…The safety, but not the efficacy, of OraVerse has been evaluated in pediatric patients under the age of 6 years old. Dosages in pediatric patients may need to be limited based on body weight [13].…”
Section: Pediatric Usementioning
confidence: 99%
“…The pharmacokinetics of OraVerse after administration of more than 1 cartridge (0.4 mg) has not been studied in children [13].…”
Section: Pediatricsmentioning
confidence: 99%